SiteOne Therapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 22

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1B

SiteOne Therapeutics General Information

Description

Developer of novel pain therapeutics designed to offer treatment for acute and chronic pain. The company's drugs provide treatment for neuropathic pain through novel pain therapeutics without the limitations of existing drugs, such as opioids, enabling healthcare professionals to deliver an optimal treatment to their patients and improve efficiency.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 280 Utah Avenue
  • Suite 250
  • South San Francisco, CA 94080
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 280 Utah Avenue
  • Suite 250
  • South San Francisco, CA 94080
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SiteOne Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Merger/Acquisition 28-Jul-2025 $1B Completed Clinical Trials - Phase 1
15. Later Stage VC (Series C) 18-Dec-2024 Completed Clinical Trials - Phase 1
14. Later Stage VC 01-Jan-2024 Completed Clinical Trials - Phase 1
13. Grant 19-May-2023 Completed Clinical Trials - Phase 1
12. Grant 01-Sep-2021 Completed Clinical Trials - Phase 1
11. Grant 11-May-2021 Completed Clinical Trials - Phase 1
10. Grant 10-Oct-2019 Completed Clinical Trials - Phase 1
9. Grant 01-May-2019 Completed Clinical Trials - Phase 1
8. Grant 01-Jan-2018 $1.49M $17.7M Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B) 08-Jan-2017 $15M $17.7M Completed Clinical Trials - Phase 1
To view SiteOne Therapeutics’s complete valuation and funding history, request access »

SiteOne Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A1
Series A 1,315,638 $0.001000 $0.09 $1.15 $1.15 1x $1.15 15.37%
To view SiteOne Therapeutics’s complete cap table history, request access »

SiteOne Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel pain therapeutics designed to offer treatment for acute and chronic pain. The company's drugs provide
Drug Discovery
South San Francisco, CA
22 As of 2025

Boston, MA
 

Plymouth, MN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SiteOne Therapeutics Competitors (16)

One of SiteOne Therapeutics’s 16 competitors is Centrexion Therapeutics, a Venture Capital-Backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrexion Therapeutics Venture Capital-Backed Boston, MA
Frenelle Pharma Venture Capital-Backed Plymouth, MN
Cerecin Venture Capital-Backed Broomfield, CO
Curemark Venture Capital-Backed New York, NY
Neuropn Therapeutics Corporation Alpharetta, GA
You’re viewing 5 of 16 competitors. Get the full list »

SiteOne Therapeutics Patents

SiteOne Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025376454-A1 Substituted cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain Pending 17-May-2024
WO-2025240895-A1 Substituted cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain Pending 17-May-2024
AU-2025211735-A1 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain Pending 24-Jan-2024
WO-2025160286-A1 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain Pending 24-Jan-2024
EP-4514789-A1 ? ?v?bicyclic heterocyclic amide inhibitors of na1.8 for the treatment of pain Pending 25-Apr-2022 C07D401/04
To view SiteOne Therapeutics’s complete patent history, request access »

SiteOne Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SiteOne Therapeutics Former Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds
2M Collective Family Office Minority
Amgen Corporation Minority
BSQUARED Capital Family Office Minority
Biobrit Venture Capital Minority
Mission Bay Capital Venture Capital Minority
You’re viewing 5 of 20 investors. Get the full list »

SiteOne Therapeutics FAQs

  • When was SiteOne Therapeutics founded?

    SiteOne Therapeutics was founded in 2010.

  • Where is SiteOne Therapeutics headquartered?

    SiteOne Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of SiteOne Therapeutics?

    SiteOne Therapeutics has 22 total employees.

  • What industry is SiteOne Therapeutics in?

    SiteOne Therapeutics’s primary industry is Drug Discovery.

  • Is SiteOne Therapeutics a private or public company?

    SiteOne Therapeutics is a Private company.

  • What is the current valuation of SiteOne Therapeutics?

    The current valuation of SiteOne Therapeutics is .

  • What is SiteOne Therapeutics’s current revenue?

    The current revenue for SiteOne Therapeutics is .

  • How much funding has SiteOne Therapeutics raised over time?

    SiteOne Therapeutics has raised $118M.

  • Who are SiteOne Therapeutics’s investors?

    2M Collective, Amgen, BSQUARED Capital, Biobrit, and Mission Bay Capital are 5 of 20 investors who have invested in SiteOne Therapeutics.

  • Who are SiteOne Therapeutics’s competitors?

    Centrexion Therapeutics, Frenelle Pharma, Cerecin, Curemark, and Neuropn Therapeutics are some of the 16 competitors of SiteOne Therapeutics.

  • When was SiteOne Therapeutics acquired?

    SiteOne Therapeutics was acquired on 28-Jul-2025.

  • Who acquired SiteOne Therapeutics?

    SiteOne Therapeutics was acquired by Lilly USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process